Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- SEMI-ANNUAL BUSINES RESULTS
December 1, 2003
- Teijin: Sales Up, but Operating Profits Hit by R&D Costs
December 1, 2003
- Hearings on Late-night, Early-morning Drug Sales Held
December 1, 2003
- Sawai: Favorable GE Market Drives Strong Growth in Sales, Profits
December 1, 2003
- OTC NEWS IN BRIEF
December 1, 2003
- Kuraya Sanseido: Sales, Net Profits Up Slightly
December 1, 2003
- PRESS SEMINAR
December 1, 2003
- Kissei: Sales Increase 1.3%, Profits Up 281.2%
December 1, 2003
- WORLD NEWS IN BRIEF
December 1, 2003
- Nippon Shinyaku: Sales Up Slightly, Profits Hit by Higher Costs
December 1, 2003
- Rewards for Innovativeness in New Drugs to Be Needed: Mr Ager of EFPIA
December 1, 2003
- Kaken: Ordinary Profits Down, but R&D Tax Credit Boosts Net Profits
December 1, 2003
- ICH-6 in Osaka Focuses on New Horizons and Future Challenges (1)
December 1, 2003
- Meiji Seika: Drug Division Sales Up 6.5% to \49.5 Bil.
December 1, 2003
- Chuikyo Discusses NPA Recommendation, Consumer Prices
December 1, 2003
- Suzuken: Consolidated Sales Up 15% to \558.1 Bil.
December 1, 2003
- REGULATORY NEWS IN BRIEF
December 1, 2003
- Toho: Sales Up 17.4%, Net Profits Up 44.9%
December 1, 2003
- CORPORATE ROUNDUP NEWS IN BRIEF
December 1, 2003
- Takeover of Nikken Chemicals to Make Kowa Strengthen Marketing, R&D: President Miwa
December 1, 2003
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…